Elsevier

Life Sciences

Volume 34, Issue 16, 16 April 1984, Pages 1529-1540
Life Sciences

Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics

https://doi.org/10.1016/0024-3205(84)90607-6Get rights and content

Abstract

Neuroleptics such as thioxanthenes (cis(Z)-flupentixol and cis(Z)-clopenthixol) and phenothiazines (fluphenazine and perphenazine), which block both dopamine (DA) D-1 and D-2 receptors and the butyrophenones (haloperidol and spiroperidol), which block D-2 receptors only, are equipotent both behaviorally and clinically. A new compound SCH 23390 which selectively blocks DA D-1 receptors, resembles many neuroleptics in its pharmacological profile: antistereotypic effects in mice, rats and dogs, cataleptogenic effect and inhibitory effect on amphetamine circling. In contrast SCH 23390 has no effect on apomorphine-induced vomiting in dogs and little effects on 6-OHDA-denervated supersensitive DA receptors, stimulated by the DA agonist 3-PPP. In a series of experiments where methylphenidate-induced stereotyped gnawing in mice was inhibited by neuroleptics, it was shown that concomitant treatment with scopolamine or diazepam attenuated the effect of butyrophenones (D-2 antagonists). The same treatment attenuated the effect of phenothiazines, to a lesser extent, and hardly attenuated the effect of thioxanthenes and SCH 23390 at all. It is concluded that DA D-1 receptors are as important as D-2 receptors for the expression of neuroleptic activity in most animal models believed to be predictive of antipsychotic and extrapyramidal side-effect potential. However, the D-1 antagonist is less sensitive than D-2 antagonists to antimuscarinic compounds and benzodiapines.

References (45)

  • J. Arnt

    Eur. J. Pharmacol.

    (1983)
  • J. Scheel-Krüger et al.

    Eur. J. Pharmacol.

    (1977)
  • A.V. Christensen et al.

    Life Sci.

    (1979)
  • A.V. Christensen et al.

    Brain Research Bulletin

    (1980)
  • J. Hyttel

    Advances in the Biosciences

    (1982)
  • J. Hyttel

    Eur. J. Pharmacol.

    (1983)
  • O. Svendsen

    Eur. J. Pharm.

    (1979)
  • J. Arnt et al.

    Europ. J. Pharmacol.

    (1981)
  • P.E. Setler et al.

    Europ. J. Pharmacol.

    (1978)
  • J. Lehmann et al.

    Europ. J. Pharmacol.

    (1983)
  • J. Scheel-Krüger et al.

    Life Sci.

    (1978)
  • P.A.J. Janssen et al.

    Arzneim.-Forsch.

    (1965)
  • P.A.J. Janssen et al.

    Arzneim.-Forsch.

    (1965)
  • A. Randrup et al.

    Nature

    (1966)
  • J. Scheel-Krügger

    Eur. J. Pharmac.

    (1971)
  • V. Pedersen et al.

    Acta pharmacol. et toxicol.

    (1972)
  • A.V. Christensen et al.

    Pharmacy International

    (1982)
  • R. Fog

    Munksgård, Copenhagen

    (1972)
  • J. Arnt

    Br. J. Pharmac.

    (1982)
  • J. Arnt

    Acta pharmacol. et toxicol.

    (1982)
  • A. Carlsson et al.

    Acta pharmacol. et toxicol.

    (1963)
  • A. Carlsson

    Pharmacol. Rev.

    (1966)
  • Cited by (0)

    View full text